Prellis Biologics has raised $8.7 million in a new round of equity financing, according to a recently posed SEC filing.
The San Francisco-based company is developing ultra-fast high-resolution holographic laser printing technology intended for use in creating human organs and tissues, according to its website.
Prellis Biologics offers a number of products based around vascularized tissue structures and extracellular matrices intended to grow human tissues and cells, according to the site.
A total of 11 anonymous investors participated in the round, with the first date of sale noted as having occurred on March 12.
The company is looking to raise an additional $475,000 in the round which would bring the total raised up to $9.2 million, according to the SEC filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.